How has been the historical performance of Epigral?

Answer:The historical performance of Epigral shows significant growth in net sales and profitability over the years.

Breakdown:
Epigral's net sales have increased from 828.60 Cr in Mar'21 to 2,550.13 Cr in Mar'25, demonstrating a strong upward trend. Total operating income followed a similar pattern, rising from 828.60 Cr in Mar'21 to 2,550.13 Cr in Mar'25. The company's total expenditure, excluding depreciation, also grew from 567.28 Cr in Mar'21 to 1,839.41 Cr in Mar'25, reflecting the increased scale of operations. Operating profit (PBDIT) rose from 263.51 Cr in Mar'21 to 725.93 Cr in Mar'25, while profit before tax increased from 160.86 Cr to 540.10 Cr in the same period. The profit after tax showed a notable rise from 100.84 Cr in Mar'21 to 356.70 Cr in Mar'25. Additionally, earnings per share (EPS) improved significantly from 24.27 in Mar'21 to 82.91 in Mar'25. On the balance sheet, total assets grew from 1,448.70 Cr in Mar'21 to 3,152.44 Cr in Mar'25, while total liabilities increased from 1,448.70 Cr to 3,152.44 Cr, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities also showed a positive trend, increasing from 229.00 Cr in Mar'21 to 440.00 Cr in Mar'25, contributing to a net cash inflow of 15.00 Cr in Mar'25. Overall, Epigral has demonstrated robust growth in sales, profits, and asset base over the historical period.